A clinical commentary in Trends in Endocrinology and Metabolism raises a pointed concern about GLP-1 receptor agonist use in older adults: that cardiovascular and renal benefits may come at the cost of muscle mass, nutritional resilience, and functional independence. The authors propose a geriatric-informed prescribing framework that redefines treatment success beyond weight reduction alone.
This perspective arrives at a critical inflection point. GLP-1 receptor agonists — semaglutide, tirzepatide, and their class — have demonstrated robust cardiorenal protection in landmark trials like LEADER, SUSTAIN-6, and SELECT, but those trials skewed toward middle-aged adults with established disease. Sarcopenia already affects 10–20% of adults over 65, and drug-induced anorexia compounds lean mass loss at a stage when muscle reserve directly predicts fall risk, hospitalization, and mortality. The appetite-suppressing mechanism that makes GLP-1 agonists effective for weight loss becomes potentially hazardous when protein intake is already marginal.
Critically, this is a perspective piece, not original trial data — no new cohort, no effect sizes, no controlled outcomes. Its value is conceptual: it signals a gap in the evidence base and pushes clinicians to weigh functional endpoints alongside metabolic ones. The call for geriatric-informed prescribing — incorporating frailty screening, body composition monitoring, and nutritional co-intervention — is clinically sound and overdue. Incremental in novelty, but strategically important for translating GLP-1 evidence into safe older-adult practice.